Business
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
RICHMOND, Va., April 02, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the ur
About this update from Aditxt, Inc.
[{"type":"text","content":"Event exploring the increasing risk of emerging infectious diseases","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"RICHMOND, Va., April 02, 2025--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatments, and the role of partnerships in accelerating promising health innovations.","length":666,"tagName":"p"},{"type":"text","content":"Mr. Cilla will join to discuss how Appili is advancing a portfolio of opportunities in the area of public health. The event will also highlight Aditxt’s role as a strategic growth partner, seeking to accelerate promising health innovations and expand access to life-saving treatments worldwide.","length":294,"tagName":"p"},{"type":"text","content":"Additionally, the discussion will provide insights into Appili’s non-dilutive funding capabilities, highlighting $33.2 million received in prior government awards, $117 million in new funding applications (link to press release), and an update to its United States Air Force Academy ("USAFA") Cooperative Agreement for ATI-1701, biodefense vaccine candidate. This USAFA update features an increased General & Administrative ("G&A") overhead recovery rate, applied retroactively to past and future invoices. The increase in the allowable G&A overhead recovery rate represents a potential significant benefit, which would enable Appili to optimize funding resources and advance ATI-1701.","length":717,"tagName":"p"},{"type":"text","content":"Participants are encouraged to register in advance online:","length":58,"tagName":"p"},{"type":"text","content":"Registration: Click here to register.","length":37,"tagName":"p"},{"type":"text","conte...